BDBM345357 1-[1-[4-(3-chlorophenyl)phe-nyl]sulfonyl-4,5-dihydroimidazol-2-yl]-4-cyclobutyl-piperazine::US10202354, Example 22
SMILES: Clc1cccc(c1)-c1ccc(cc1)S(=O)(=O)N1CCN=C1N1CCN(CC1)C1CCC1
InChI Key: InChIKey=QCCBUARERXTMMD-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lysine-specific demethylase 2B (Homo sapiens (Human)) | BDBM345357 (1-[1-[4-(3-chlorophenyl)phe-nyl]sulfonyl-4,5-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.120 | n/a | n/a | n/a | n/a | n/a | n/a |
GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. US Patent | Assay Description Full length KDM2B was cloned, expressed, and purified to homogeneity. Compound inhibition of KDM2B demethylase activity was assessed by monitoring th... | US Patent US10202354 (2019) BindingDB Entry DOI: 10.7270/Q2VT1V62 | |||||||||||
More data for this Ligand-Target Pair |